Papi, Alberto
Blasi, Francesco
Canonica, Giorgio Walter
Morandi, Luca
Richeldi, Luca
Rossi, Andrea
Article History
Received: 18 March 2020
Accepted: 5 August 2020
First Online: 15 August 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: AP reports grants, personal fees, non-financial support and payment for advisory board membership, consultancy, payment for lectures, grants for research, and travel expenses reimbursement from Chiesi, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Mundipharma and Teva, and personal fees and non-financial support from Menarini, Novartis, Zambon and Sanofi.FB reports having received in the last three years research grants as well as lecture or advisory board fees from: Alk-Abelló, AstraZeneca, Boehringer Ingelheim, Chiesi, Guidotti, Glaxo Smith Kline, Grifols, Menarini, Novartis, Sanofi, Valeas, Zambon.GWC reports having received in the last 3 years research grants as well as lecture or advisory board fees from: A. Menarini, Alk-Abelló, AstraZeneca-Medimmune, Boehringer Ingelheim, Chiesi Farmaceutici, Genentech, Guidotti-Malesci, Glaxo Smith Kline, Hal Allergy, Merck Sharp & Dohme, Mundipharma, Novartis, Orion, Sanofi-Aventis, Sanofi Genzyme/Regeneron, Stallergenes-Greers, UCB Pharma, Uriach Pharma, Valeas.LR Receipt of grants/research supports: Roche, Boehringer Ingelheim.Receipt of honoraria or consultation fees: Boehringer Ingelheim, Roche, Biogen, FibroGen,Sanofi-Aventis, Anthera, Promedior, ImmuneWorks, Asahi-Kasei, Bayer, Celgene, RespiVant,Nitto, Bristol Myers Squibb, Prometic, Pliant Therapeutics, Toray, Global Blood Therapeutics,Zambon, Veracyte, Acceleron, CSL Behring.LM and AR reports no conflicts of interest in the last 3 years.